CALC CalciMedica, Inc. stock chart & analysis
Conviction 45HealthcareScan · Tue, Nov 17, 2026CalciMedica, Inc. (CALC) closed at $1.23 (+2.94%) on Nov 17, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 43, RS Rating 4, -96.6% from its 52-week high, -96.3% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why CALC moved
From the StockSetups movers recaps that covered CALC, newest first. A recap states what was known that day.
- Close+27.8%
Two simultaneous announcements filed on June 24, 2026 (press releases via PR Newswire and two 8-K filings with the SEC) drove the move:
Top Stock Movers Today — June 26, 2026: Why SDOT, PCLA, ILLR, CALC & NNOX Surged →
Financials as of Wed, Sep 30, 2026 · quarterly.
CALC technical analysis
Trend
CALC is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 18.3% below the 50-day ($1.50) and 58.4% below the 200-day ($2.95). ADX(14) at 21 points to a moderate trend. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 43, in the bearish half of its range. MACD crossed below its signal line one session ago. Its RS Rating of 4 puts its weighted 12-month performance ahead of about 4% of the US market.
Volume and volatility
Volume on the latest session ran 0.0× its 20-day average. It trades about $113,689 a day on average. ATR(14) is $0.1825, 14.9% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (-0.19) shows distribution.
Key levels
The chart pattern's support is $1.02 and its resistance $1.77. The 52-week range is $1.00 to $36.00; price is 96.6% below the high and 22.5% above the low. The VWAP anchored at the 52-week high is $4.24, above price.
Performance
CALC returned -10.6% (1 week), +20.1% (1 month), -60.0% (3 months), -60.3% (6 months), -91.8% (1 year), -96.3% (year to date).
About CalciMedica, Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Pharmaceutical Preparations · Listed 2020 · 16 employees
Insider activity
SEC Form 4 transactions in CALC
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Roberts Eric W CHIEF BUSINESS OFFICER · Employee Stock Option (Right to Buy) · 2026-11-03 | Grant | 180K | — | 2026-11-03 | 2026-11-05 |
WILSON ROBERT N Director · Director Stock Option (Right to Buy) · 2026-10-01 | Grant | 20K | — | 2026-10-01 | 2026-10-05 |
Shaw Allan Director · Director Stock Option (Right to Buy) · 2026-10-01 | Grant | 20K | — | 2026-10-01 | 2026-10-05 |
Zaytsev Evgeny Director · Director Stock Option (Right to Buy) · 2026-10-01 | Grant | 20K | — | 2026-10-01 | 2026-10-05 |
Glicklich Alan Director · Director Stock Option (Right to Buy) · 2026-10-01 | Grant | 20K | — | 2026-10-01 | 2026-10-05 |
Guerard Frederic Director · Director Stock Option (Right to Buy) · 2026-10-01 | Grant | 20K | — | 2026-10-01 | 2026-10-05 |
ALAFI CAPITAL CO LLC 10% owner · Series A Warrants · 2026-08-19 | Grant | 3.53M | — | 2026-08-19 | 2026-08-24 |
ALAFI CAPITAL CO LLC 10% owner · Series B Warrants · 2026-08-19 | Grant | 3.53M | — | 2026-08-19 | 2026-08-24 |
WILSON ROBERT N Director · Warrant · 2026-08-19 | Grant | 1.18M | — | 2026-08-19 | 2026-08-21 |
WILSON ROBERT N Director · Director Stock Option (Right to Buy) · 2026-08-19 | Grant | 10K | — | 2026-08-19 | 2026-08-21 |
SEC filings
EDGAR filings in CALC · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.